The VLP formulation administered as a prophylactic vaccine reduced spontaneous development of mammary carcinomas by 50%–100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild type mice [100]. This evidence concerns the gene ERBB2 and breast carcinoma.